Andrew X Zhu

Andrew X Zhu

UNVERIFIED PROFILE

Are you Andrew X Zhu?   Register this Author

Register author
Andrew X Zhu

Andrew X Zhu

Publications by authors named "Andrew X Zhu"

Are you Andrew X Zhu?   Register this Author

100Publications

3261Reads

32Profile Views

Predictors of adjuvant treatment and survival in patients with intrahepatic cholangiocarcinoma who undergo resection.

Am J Surg 2019 Nov 4;218(5):959-966. Epub 2019 Mar 4.

Department of Surgery, Massachusetts General Hospital, Boston, MA, 02114, USA; Newton Wellesley Hospital, Newton, MA 02462, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjsurg.2019.02.036DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6722029PMC
November 2019

Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.

Lancet Gastroenterol Hepatol 2019 Sep 9;4(9):711-720. Epub 2019 Jul 9.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2468-1253(19)30189-XDOI Listing
September 2019

Nivolumab with gemcitabine plus cisplatin for biliary cancers: as easy as ABC?

Lancet Gastroenterol Hepatol 2019 Aug 17;4(8):575-577. Epub 2019 May 17.

Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA 02114, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2468-1253(19)30148-7DOI Listing
August 2019

Biology and significance of alpha-fetoprotein in hepatocellular carcinoma.

Liver Int 2019 Aug 22. Epub 2019 Aug 22.

Massachusetts General Hospital Cancer Center, Harvard Medical Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14223DOI Listing
August 2019

Another Treatment Option for Advanced Hepatocellular Carcinoma With Portal Vein Thrombosis in China.

JAMA Oncol 2019 Jul;5(7):938-939

Department of Medicine, Massachusetts General Hospital Cancer Center, Boston.

View Article

Download full-text PDF

Source
http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jam
Publisher Site
http://dx.doi.org/10.1001/jamaoncol.2019.0249DOI Listing
July 2019

RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma.

Future Oncol 2019 Jun 10;15(16):1811-1822. Epub 2019 Apr 10.

Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2019-0097DOI Listing
June 2019

Has PD-1 MET Its Match in Hepatocellular Carcinoma?

Gastroenterology 2019 05 26;156(6):1563-1565. Epub 2019 Mar 26.

Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00165085193458
Publisher Site
http://dx.doi.org/10.1053/j.gastro.2019.03.029DOI Listing
May 2019

Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances.

Hepatology 2019 Apr 25;69(4):1803-1815. Epub 2019 Mar 25.

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hep.30289
Publisher Site
http://dx.doi.org/10.1002/hep.30289DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433548PMC
April 2019

Is It Time to Reconsider the Milan Criteria for Selecting Patients With Hepatocellular Carcinoma for Deceased-Donor Liver Transplantation?

Hepatology 2019 Mar;69(3):1324-1336

Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30278DOI Listing
March 2019

Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma.

Cardiovasc Intervent Radiol 2018 Nov 29;41(11):1799-1802. Epub 2018 May 29.

Department of Radiology, Massachusetts General Hospital, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00270-018-1993-1DOI Listing
November 2018

Evolving Systemic Therapy in Hepatocellular Carcinoma: Current Management and Opportunities for Integration With Radiotherapy.

Semin Radiat Oncol 2018 10;28(4):332-341

Massachusetts General Hospital, Division of Hematology-Oncology, Department of Medicine, Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semradonc.2018.06.006DOI Listing
October 2018

Radiotherapy for Biliary Tract Cancers.

Semin Radiat Oncol 2018 10;28(4):342-350

Massachusetts General Hospital, Department of Radiation Oncology, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10534296183004
Publisher Site
http://dx.doi.org/10.1016/j.semradonc.2018.06.003DOI Listing
October 2018

Current status and evolving treatment for primary liver cancers.

Chin Clin Oncol 2018 Oct;7(5):47

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://cco.amegroups.com/article/view/21987/21531
Publisher Site
http://dx.doi.org/10.21037/cco.2018.10.05DOI Listing
October 2018

Pilot study on the impact of F18-labeled thymidine PET/CT on gross tumor volume identification and definition for pancreatic cancer.

Pract Radiat Oncol 2018 May - Jun;8(3):179-184. Epub 2017 Sep 18.

Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prro.2017.09.008DOI Listing
September 2018

Gallbladder toxicity and high-dose ablative-intent radiation for liver tumors: Should we constrain the dose?

Pract Radiat Oncol 2017 Sep - Oct;7(5):e323-e329. Epub 2017 Feb 9.

Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prro.2017.02.001DOI Listing
May 2018

Hepatocellular Carcinoma With Portal Venous Invasion: Radiating New Hope?

JAMA Oncol 2018 05;4(5):669-670

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston.

View Article

Download full-text PDF

Source
http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jam
Publisher Site
http://dx.doi.org/10.1001/jamaoncol.2018.0007DOI Listing
May 2018

Tivantinib for advanced hepatocellular carcinoma: is MET still a viable target?

Lancet Oncol 2018 05 3;19(5):591-592. Epub 2018 Apr 3.

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30249-3DOI Listing
May 2018

Can smart nanomedicine deliver effective targeted cytotoxic treatments to hepatocellular carcinomas while reducing the liver damage?

Hepatology 2018 03 30;67(3):826-828. Epub 2018 Jan 30.

Edwin L. Steele Laboratories, Department of Radiation Oncology.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.29617DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5826834PMC
March 2018

AASLD guidelines for the treatment of hepatocellular carcinoma.

Hepatology 2018 01;67(1):358-380

Digestive and Liver Diseases Division, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.29086DOI Listing
January 2018

Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: A systematic review and meta-analysis.

Hepatology 2018 01;67(1):422-435

Evidence-based Practice Center, Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hep.29486
Publisher Site
http://dx.doi.org/10.1002/hep.29486DOI Listing
January 2018

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.

J Clin Oncol 2018 01 28;36(3):276-282. Epub 2017 Nov 28.

Milind Javle and Rachna T. Shroff, The University of Texas MD Anderson Cancer Center, Houston, TX; Maeve Lowery and Ghassan K. Abou-Alfa, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York, NY; Karl Heinz Weiss and Christoph Springfeld, Universitäts Klinikum Heidelberg, Heidelberg, Germany; Mitesh J. Borad, Ramesh K. Ramanathan, and Tanios Bekaii-Saab, Mayo Clinic, Phoenix, AZ; Lipika Goyal and Andrew X. Zhu, Massachusetts General Hospital Cancer Center, Boston, MA; Saeed Sadeghi and Richard S. Finn, David Geffen School of Medicine at UCLA; Anthony El-Khoueiry, USC Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles; Robin Kate Kelley, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Teresa Macarulla, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Ivan Borbath, Cliniques Universitaires Saint-Luc, Brussels; Eric Van Cutsem, University Hospitals Gasthuisberg and KU Leuven, Leuven, Belgium; Su Pin Choo, National Cancer Centre of Singapore, Singapore; Do-Youn Oh, Seoul National University, Seoul, South Korea; Philip A. Philip, Karmanos Cancer Institute, Detroit, MI; Li-Tzong Chen, National Institute of Cancer Research and National Cheng Kung University Hospital, Tainan; Kun-Huei Yeh, National Taiwan University Hospital Cancer Center, and Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan; Thanyanan Reungwetwattana, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Kristen Ciombor, The Ohio State University Wexner Medical Center, Columbus, OH; and Anuradha Patel, Suman Sen, Dale Porter, and Randi Isaacs, Novartis Pharmaceuticals Corporation, East Hanover, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.5009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075847PMC
January 2018

Hepatocellular Carcinoma with Macrovascular Invasion: Defining the Optimal Treatment Strategy.

Liver Cancer 2017 Nov 19;6(4):360-374. Epub 2017 Oct 19.

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000481315DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5704715PMC
November 2017

New Horizons for Precision Medicine in Biliary Tract Cancers.

Cancer Discov 2017 09 17;7(9):943-962. Epub 2017 Aug 17.

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-17-0245DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586506PMC
September 2017

Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype.

J Natl Cancer Inst 2017 09;109(9)

Department of Radiation Oncology, Department of Pathology, Division of Biostatistics, Department of Medicine, Division of Medical Oncology, Department of Medicine, Department of Radiology, and Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA; Harvard Radiation Oncology Program, Harvard Medical School, Boston, MA; Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djx031DOI Listing
September 2017

Functional Imaging and Assessment of Antitumor Activity in Systemic Therapy for Hepatocellular Carcinoma.

Semin Liver Dis 2017 08 28;37(3):259-274. Epub 2017 Aug 28.

Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0037-1606254DOI Listing
August 2017

The treatment path in hepatocellular carcinoma.

Clin Adv Hematol Oncol 2017 Aug;15 Suppl 9(8):1-20

Indiana University School of Medicine, Indianapolis, Indiana.

View Article

Download full-text PDF

Source
August 2017

Recent developments in systemic therapy for hepatocellular carcinoma.

Authors:
Andrew X Zhu

Clin Adv Hematol Oncol 2017 Aug;15 Suppl 9(8):7-13

Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
August 2017

Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma.

Immunotherapy 2016 11;8(3):299-313. Epub 2016 Feb 11.

Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt.15.126DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5619018PMC
December 2016

Comparison of hepatocellular carcinoma in Eastern versus Western populations.

Cancer 2016 Nov 13;122(22):3430-3446. Epub 2016 Sep 13.

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.30237
Publisher Site
http://dx.doi.org/10.1002/cncr.30237DOI Listing
November 2016

Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma.

J Hepatol 2016 08 27;65(2):296-304. Epub 2016 Apr 27.

Novartis Institutes for Biomedical Research, Cambridge, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2016.04.015DOI Listing
August 2016

Transarterial Chemoembolization in the Coming Era of Decreased Reimbursement for Readmissions.

J Am Coll Radiol 2016 Aug 18;13(8):915-21. Epub 2016 Jun 18.

Biomaterials Innovation Research Center, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, Massachusetts; Division of Vascular and Interventional Radiology, Mayo Clinic, Scottsdale, Arizona. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacr.2016.04.030DOI Listing
August 2016

The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.

Oncotarget 2016 Jul;7(29):46750-46767

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://www.oncotarget.com/fulltext/8775
Publisher Site
http://dx.doi.org/10.18632/oncotarget.8775DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216834PMC
July 2016

Liver-Directed Radiotherapy for Hepatocellular Carcinoma.

Liver Cancer 2016 Jul 10;5(3):198-209. Epub 2016 May 10.

Department of Radiation Oncology, Massachusetts General Hospital, Boston, Mass., USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000367764DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960357PMC
July 2016

Water-Exchange-Modified Kinetic Parameters from Dynamic Contrast-Enhanced MRI as Prognostic Biomarkers of Survival in Advanced Hepatocellular Carcinoma Treated with Antiangiogenic Monotherapy.

PLoS One 2015 14;10(9):e0136725. Epub 2015 Sep 14.

3D Imaging Research, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0136725PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4569468PMC
June 2016

Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise.

Oncologist 2016 05 21;21(5):594-9. Epub 2016 Mar 21.

Dana-Farber Cancer Institute, Boston, Massachusetts, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0446DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861366PMC
May 2016

CT-Guided Percutaneous Microwave Ablation of Tumors in the Hepatic Dome: Assessment of Efficacy and Safety.

J Vasc Interv Radiol 2016 Apr 28;27(4):496-502; quiz 503. Epub 2016 Feb 28.

Department of Radiology, Division of Interventional Radiology, Massachusetts General Hospital, White 270, Boston, MA 02114.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jvir.2016.01.010DOI Listing
April 2016

Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

J Clin Oncol 2016 Feb 14;34(5):460-8. Epub 2015 Dec 14.

Theodore S. Hong, Jennifer Y. Wo, Beow Y. Yeap, Erin I. McDonnell, Lawrence S. Blaszkowsky, Eunice L. Kwak, Jill N. Allen, Jeffrey W. Clark, Lipika Goyal, Janet E. Murphy, John A. Wolfgang, Lorraine C. Drapek, Ronald S. Arellano, John T. Mullen, Sam S. Yoon, Kenneth K. Tanabe, Cristina R. Ferrone, David P. Ryan, Thomas F. DeLaney, and Andrew X. Zhu, Massachusetts General Hospital, Harvard Medical School; Harvey J. Mamon, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Edgar Ben-Josef, University of Pennsylvania Hospital, Philadelphia, PA; and Milind M. Javle and Christopher H. Crane, University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/12/11/JCO.2015.64
Web Search
http://jco.ascopubs.org/content/suppl/2015/12/14/JCO.2015.64
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.64.2710
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.64.2710DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872014PMC
February 2016

Advanced Hepatocellular Carcinoma: Perfusion Computed Tomography-Based Kinetic Parameter as a Prognostic Biomarker for Prediction of Patient Survival.

J Comput Assist Tomogr 2015 Sep-Oct;39(5):687-96

From the *3D Imaging Research, Department of Radiology, Massachusetts General Hospital and Harvard Medical School; †Division of Abdominal Imaging and Intervention, Department of Radiology, Massachusetts General Hospital; and ‡Massachusetts General Hospital Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/RCT.0000000000000288DOI Listing
December 2015

Dynamic Contrast-Enhanced MRI Kinetic Parameters as Prognostic Biomarkers for Prediction of Survival of Patient with Advanced Hepatocellular Carcinoma: A Pilot Comparative Study.

Acad Radiol 2015 Nov 23;22(11):1344-60. Epub 2015 Jul 23.

3D Imaging Research, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, 25 New Chardon St, Suite 400C, Boston, MA 02114. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.acra.2015.05.012DOI Listing
November 2015

Consensus conference on hilar cholangiocarcinoma.

HPB (Oxford) 2015 Aug;17(8):666-8

Massachusetts General Hospital Cancer Center/Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hpb.12451DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4527851PMC
August 2015

Chemotherapy and antiangiogenics in biliary tract cancer.

Lancet Oncol 2015 Aug 12;16(8):882-3. Epub 2015 Jul 12.

Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(15)00093-5DOI Listing
August 2015

An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis.

Nat Protoc 2015 Aug 23;10(8):1264-74. Epub 2015 Jul 23.

Department of Radiation Oncology, Steele Laboratories for Tumor Biology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nprot.2015.080DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800979PMC
August 2015

CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.

Hepatology 2015 May 20;61(5):1591-602. Epub 2015 Mar 20.

E.L. Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Institute of Biomedical Engineering, National Tsing Hua University, Hsinchu, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.27665DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4406806PMC
May 2015

Microsatellite instability in gallbladder carcinoma.

Virchows Arch 2015 Apr 14;466(4):393-402. Epub 2015 Feb 14.

Pathology Service, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Warren 256, Boston, MA, 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00428-015-1720-0DOI Listing
April 2015

Safety and efficacy of 70-150 μm and 100-300 μm drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma.

J Vasc Interv Radiol 2015 Apr 18;26(4):516-22. Epub 2015 Feb 18.

Section of Interventional Radiology, Department of Radiology, Massachusetts General Hospital and Harvard Medical School. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10510443140121
Publisher Site
http://dx.doi.org/10.1016/j.jvir.2014.12.020DOI Listing
April 2015

Measuring treatment response to systemic therapy and predicting outcome in biliary tract cancer: comparing tumor size, volume, density, and metabolism.

AJR Am J Roentgenol 2015 Apr;204(4):776-81

1 Department of Radiology, Division of Abdominal Imaging and Intervention, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St, White 270, Boston, MA 02114.

View Article

Download full-text PDF

Source
http://www.ajronline.org/doi/10.2214/AJR.14.13223
Publisher Site
http://dx.doi.org/10.2214/AJR.14.13223DOI Listing
April 2015

Radiotherapy for liver tumors.

Hepat Oncol 2015 Apr 20;2(2):133-146. Epub 2015 Apr 20.

Massachusetts General Hospital, Department of Radiation Oncology, 32 Fruit St, Yawkey 7, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/hep.15.7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095425PMC
April 2015

Future directions in the treatment of cholangiocarcinoma.

Authors:
Andrew X Zhu

Best Pract Res Clin Gastroenterol 2015 Apr 19;29(2):355-61. Epub 2015 Feb 19.

Tucker Gosnell Center for Gastrointestinal Cancers, Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Boston, MA, 02114, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2015.02.010DOI Listing
April 2015

YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression.

Cell Rep 2015 Mar 12;10(10):1692-1707. Epub 2015 Mar 12.

Cancer Center, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA 02114, USA; Center for Regenerative Medicine, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA 02114, USA; Department of Medicine, Harvard Medical School, Boston, MA 02114, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2015.02.027DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4565791PMC
March 2015

SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.

J Clin Oncol 2015 Feb 29;33(6):559-66. Epub 2014 Dec 29.

Andrew X. Zhu, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Olivier Rosmorduc, Service d'Hépatologie, Hôpital Saint-Antoine, Paris; Marie-Aude Leberre, Bayer HealthCare Pharmaceuticals, Loos, France; T.R. Jeffry Evans, Beatson West of Scotland Cancer Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow; Paul J. Ross, King's College Hospital, London, United Kingdom; Armando Santoro, Humanitas Cancer Center, Milan, Italy; Flair Jose Carrilho, University of São Paulo School of Medicine, São Paulo, Brazil; Jordi Bruix and Josep M. Llovet, Barcelona Clínic Liver Cancer Group, Institut d'Investigacions Biomèdiques, August Pi i Sunyer, Hospital Clínic Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Barcelona; Josep M. Llovet, Institució Catalana de Recerca I Estudis Avançats, Catalonia, Spain; Shukui Qin, People's Liberation Army Cancer Center of Nanjing Bayi Hospital, Jiangsu, China; Paul J. Thuluvath, Institute for Digestive Health and Liver Diseases, Mercy Medical Center, Baltimore, MD; Josep M. Llovet, Mount Sinai Liver Cancer Program, Mount Sinai School of Medicine, New York, NY; Markus Jensen, Bayer Vital GmbH, Leverkusen, Germany; Gerold Meinhardt, Bayer HealthCare Pharmaceuticals, Montville, NJ; and Yoon-Koo Kang, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.7746DOI Listing
February 2015